Huadong Medicine Co Ltd banner

Huadong Medicine Co Ltd
SZSE:000963

Watchlist Manager
Huadong Medicine Co Ltd Logo
Huadong Medicine Co Ltd
SZSE:000963
Watchlist
Price: 35.73 CNY -0.86%
Market Cap: ¥62.7B

Gross Margin

33.3%
Current
Improving
by 1.1%
vs 3-y average of 32.2%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
33.3%
=
Gross Profit
¥14.4B
/
Revenue
¥43.1B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
33.3%
=
Gross Profit
¥14.4B
/
Revenue
¥43.1B

Peer Comparison

Country Company Market Cap Gross
Margin
CN
Huadong Medicine Co Ltd
SZSE:000963
62.7B CNY
Loading...
US
Mckesson Corp
NYSE:MCK
120B USD
Loading...
US
Amerisourcebergen Corp
LSE:0HF3
70.9B USD
Loading...
US
Cencora Inc
NYSE:COR
71.1B USD
Loading...
US
Cardinal Health Inc
NYSE:CAH
53.6B USD
Loading...
AU
Sigma Healthcare Ltd
ASX:SIG
32.8B AUD
Loading...
US
Henry Schein Inc
NASDAQ:HSIC
9.7B USD
Loading...
CN
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
63.9B CNY
Loading...
CN
Sinopharm Group Co Ltd
HKEX:1099
66.1B HKD
Loading...
KR
Celltrion Healthcare Co Ltd
KOSDAQ:091990
12.2T KRW
Loading...
AU
EBOS Group Ltd
OTC:EBOSY
7.1B USD
Loading...

Market Distribution

In line with most companies in China
Percentile
68th
Based on 8 314 companies
68th percentile
33.3%
Low
-2 148% — 14.3%
Typical Range
14.3% — 34.6%
High
34.6% — 775.2%
Distribution Statistics
China
Min -2 148%
30th Percentile 14.3%
Median 23%
70th Percentile 34.6%
Max 775.2%

Huadong Medicine Co Ltd
Glance View

Market Cap
62.7B CNY
Industry
Health Care

Huadong Medicine Co., Ltd., a key player in China's pharmaceutical landscape, was established with a vision to integrate research, development, manufacturing, and distribution of pharmaceutical products. The company operates a diverse portfolio comprising prescription medicines, over-the-counter products, and active pharmaceutical ingredients. Central to its strategy is a robust focus on innovation and quality, enabling it to effectively cater to various therapeutic areas, including oncology, endocrinology, and nephrology. Huadong Medicine benefits from its substantial investment in research and development, with state-of-the-art facilities that drive advancements and partnerships with global biotech firms, thereby underscoring its commitment to bringing cutting-edge medical solutions to the market. At the heart of Huadong Medicine’s business model is a well-coordinated infrastructure that seamlessly blends manufacturing excellence with a sophisticated distribution network. This dynamic framework ensures the efficient delivery of products across China and into international markets, supporting a significant revenue stream. Additionally, the company's active pharmaceutical ingredients (API) division forms a crucial component of its operations, supplying high-quality raw materials to both domestic and international pharmaceutical companies. By maintaining a strategic balance between product innovation and operational efficiency, Huadong Medicine not only sustains its competitive advantage but also continually scales its presence in the global pharmaceutical industry, carving out a prominent niche in an increasingly competitive arena.

Intrinsic Value
45.34 CNY
Undervaluation 21%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
33.3%
=
Gross Profit
¥14.4B
/
Revenue
¥43.1B
What is Huadong Medicine Co Ltd's current Gross Margin?

The current Gross Margin for Huadong Medicine Co Ltd is 33.3%, which is above its 3-year median of 32.2%.

How has Gross Margin changed over time?

Over the last 3 years, Huadong Medicine Co Ltd’s Gross Margin has increased from 30.6% to 33.3%. During this period, it reached a low of 30.6% on Sep 30, 2022 and a high of 33.3% on Sep 30, 2025.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett